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1. Introduction
   Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder worldwide and is characterized 
by the progressive loss of dopaminergic neurons in 
substantia nigra (SN)[1]. The clinical symptoms of PD mainly 
include rest tremors, rigidity, bradykinesia and postural 
abnormalities[2]. A growing body of evidence support the 
role in PD, of an impaired function of the mitochondria[3]. 
The exact cause of Parkinson’s disease still is not known, 
but there is a growing body of evidence that nigral neurons 
may be damaged by cytotoxic substances known as free 
radicals. Free radicals are thought to be produced locally 
within the basal ganglia and to lead to progressive damage 
to and death of substantia nigra neurons[4].
  Gentisic acid (dihydroxybenzoic acid) is an active 
metabolite of salicylic acid. Reported activity of Gentisic 
acid are antioxidant[5], antiatherogenic[6], anticancer[7], 
skeletal muscle relaxant[8]. Gentisic acid inhibits LDL 
oxidation in a concentration-dependent manner. It 
significantly inhibit the formation of cholesterol ester hydro 
peroxides in plasma, and was consumed after the depletion 
of ascorbic acid and reduced form of coenzyme Q-10 
(CoQH2-10), whereas concentrations of other antioxidants 
remained unchanged. Gentisic acid had a potent free radical 
scavenging activity with a minimal chelating effect[9]. The 
present study is carried out to evaluate the anti-Parkinson’s 
activity of Gentisic acid in different animal models due to 
anit-oxidant activity. 
2. Materials and methods
2.1. Experimental animals
  The study was conducted on Albino mice (20-25 g) & 
wistar rats (200-250 g) and maintained under standard 
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conditions (room temperature 24-27 ℃ and humidity 60-
65%) with 12 h light and dark cycle. The food in the form 
of dry pellets (Amrut Lab., Pune) and water were available 
ad libitum. The animal experiments were approved by the 
IAEC.
2.2. Chemicals and drugs
  Gentisic acid (Sigma Aldrich Pvt. Ltd, USA), Glacial acetic 
acid (Research Lab Fine chemical Industries, Mumbai, 
India), Haloperidol (marketed as SERENACE INJ.), L-dopa 
(SYNDOPA® 110, Sun Pharmaceuticals Ind. Ltd., Silvasa, 
India), Reserpine (Sigma Aldrich Pvt. Ltd., USA) 
2.3. Experiment design
2.3.1. Acute toxicity studies
  The acute toxicity study was taken from Material Safety 
Data Sheet provided by Sigma Aldrich. It is 800 mg/kg, p.o. 
for rat & 4 500 mg/kg, p.o. for mice.
2.3.2. Haloperidol induced catalepsy in mice[10]
  Albino mice of either sex weighing 20-25 g was divided 
into five groups of six animals each (n=6). The animals were 
allowed to adapt to the box for 2 min. A cataleptic behavior 
was measured with a “High bar test method”. The standard 
(L-dopa) drug was administered by intraperitoneal route 
and test drug was administered by oral route, half an hour 
prior to the Haloperidol administration. Catalepsy score 
was measured for each hour upto 4 h after Haloperidol 
administration, by gently placing both the forepaws of the 
mouse over a metal bar (diameter 2-5 mm) suspended 6 cm 
above the table top. The intensity of catalepsy was assessed 
by counting  time  in  seconds  until the mouse  brought 
both  forepaws  down  to  the table top, with a maximum 
cut-off time of 180 s.
2.3.3. Reserpine antagonism in mice[10] 
  Mice were administered with Reserpine (5 mg/kg, i.p.). 
After 24 h, test drug or standard drugs were administered 
30 min prior to observation. Mice were placed on floor 
of Perspex container having dimension 30伊26伊20 cm. 
Behavioral assessment was recorded for 10 min. In this the 
horizontal movements, rearing & grooming frequencies were 
measured. 
2.3.4. Haloperidol induce orofacial dyskinesia in rat[11] 
  Dyskinesia is characterized by vacuous chewing & tongue 
protrusion. Five groups of wistar rats (n=6) were used. 
Haloperidol was administered in the rats for a period of 21 d 
to induce oral dyskinesia. Test agent was administered once 
daily in the morning for a period of 21 d and behavioural 
assessments was performed at 7th, 14th, 21th day. 
2.3.5. Statistical analysis
  The Statistical analysis was performed by using One Way 
ANOVA followed by Dunnet’s comparison test and student 
t-test (unpaired).The values are expressed as mean 依 SEM 
and the P<0.05 was taken as significant.
3. Results  
3.1. Haloperidol induced catalepsy in mice
  Treatment with L-dopa (10 mg/kg, i.p) showed a significant 
(P<0.01) reduction in the cataleptic behavior between 60 
to 180 min of time interval as compared to the haloperidol 
treated group. Treatment with Gentisic acid showed a 
significant (P<0.01) reduction in the duration of cataleptic 
behavior dose dependently when compared to haloperidol 
treated group.
3.2. Effect of gentisic acid on reserpine antagonism in mice
  L-dopa (10 mg/kg, i.p) showed a significant (P<0.01) 
increase in the frequency of horizontal movement, rearing 
behavior and grooming behavior. Both dose of Gentisic 
acid (225 mg/kg and 450 mg/kg i.p.) showed significant 
(P<0.05) (P<0.01) respectively increase in the frequency of 
horizontal movement and rearing behavior when compared 
to the Reserpine treated group, but the effect of both dose 
of Gentisic acid on the frequency of grooming behavior was 
found to be insignificant.
3.3. Effects of gentisic acid on haloperidol induce orofacial 
dyskinesia in wistar rat
  L-dopa (10 mg/kg, i.p.) showed a significant (P<0.05) 
recovery of orofacial dyskinesia as evidenced by decrease 
in the frequency of vacuous chewing movement and tongue 
Table 1
Effect of gentisic acid in haloperidol induced catalepsy in mice.
Treatment
Catalepsy score (in seconds)
00 60 120 180 240
Vehicle 17.64依0.21   16.00依1.34  15.39依0.43  16.36依0.96   13.98依1.18
Haloperidol 16.12依6.50  159.19依4.69c 164.73依5.14c 173.60依5.12c  143.93依6.24c
L-dopa 15.17依6.68    58.26依2.16b   55.00依5.45b   44.20依2.80b 124.40依6.27
GA 225 14.58依3.47 115.16依2.15 103.00依3.76a 110.20依1.69a 142.53依3.10
GA 450 12.30依2.61    70.26依1.46b  46.50依5.38b     90.53依34.79a 117.20依3.51
The values are expressed as mean 依SEM (n=6); aP<0.05, bP<0.01, vs Haloperidol group (One way ANOVA followed by Dunnett’s test). cP<0.001 
vs vehicle group (Students‘t’ test), GA= Gentisic acid.
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protrusion. However, Gentisic acid (80 mg/kg) showed a 
significant (P<0.05) decrease in the frequency of vacuous 
chewing & tongue protrusion while Gentisic acid (40 mg/kg) 
was found to be insignificant in this respect.
4. Discussion
  Animal models of Parkinson’s disease are widely used 
to investigate its pathophysiological mechanisms and for 
exploring potential treatments[12,13]. Typically, models of PD 
are characterized by measures of akinesia, such as in bar 
test for immobility.
  Neuroleptics such as haloperidol can produce a sustained 
but reversible akinesia, due to blockade of dopamine D2 
receptors and this neuroleptic-induced Parkinsonism is a 
major side effect of their use in treatment of schizophrenia. 
D2 antagonists may act directly to reduce the ability of 
cortical and basal ganglia motor pathways to generate 
descending commands. Neuroleptics have thus been used as 
an acute model of Parkinson[14]. The central dopaminergic 
function and evaluation of dopamine agonistic activity was 
carried out by observing the cataleptic behavior in mice. 
Haloperidol blocks the dopamine D2 receptors in the brain 
and precipitates the extra pyramidal side effects that can be 
measured by “Bar test for catalepsy in mice”.
  Oral movement is an important symptom presented by a 
series of neuropsychiatric conditions including Parkinson’s 
disease[15,16]. In addition, a spontaneous aging-induced 
oral dyskinesia has been extensively described. Thus, oral 
dyskinesia may represent the behavioral manifestation 
resulting from underlying mechanisms shared by different 
neuropsychiatric conditions. Tardive Dyskinesia is a motor 
side effect of long term treatment with typical neuroleptics 
(such as haloperidol) that involves involuntary movements 
of the face, mouth and tongue, but other different parts of 
the body may also be affected[17]. Treatment with L-dopa (10 
mg/kg, i.p.) significantly attenuated the dyskinetic behavior 
in rats. Gentisic acid showed a significant attenuation in 
the frequency of tongue protrusions & VCM at higher doses 
tested.
  In the present investigation, the Reserpine treatment 
also showed effect on the stereotypic behavior in the mice 
which was characterized by decrease in frequency of 
horizontal movements, rearing and grooming behavior. The 
treatment with L-dopa showed a significant alteration in the 
stereotypic behavior when compared to Reserpine control 
group. However, the treatment with Gentisic acid shows dose 
dependant increase in the frequency of horizontal movement 
and rearing behavior when compared to the Reserpine 
control group. But, the effect of Gentisic acid on the 
frequency of grooming behavior was found to be ineffective.
It is also well known that Haloperidol blocks dopamine 
receptors and may contribute to haloperidol neurotoxicity 
due to the generation of free radicals and the increase in 
lipoperoxidation products[18]. This leads to the concomitant 
increase in the turnover of this amine which therefore 
remains available for metabolism either by auto oxidation or 
by oxidative deamination catalyzed by Monoamine oxidase 
(MAO). Consequently, it may lead to an increase in Dopamine 
(DA) metabolites along with a reduction in dopamine 
receptor activation. During this process, hydrogen peroxide 
Table 2
Effect of gentisic acid on frequency of horizontal movement, rearing behavior and grooming behavior.
Treatment
Frequency of movements/10 min
Horizontal movements Rearing behavior Grooming behavior
Vehicle 10.57依0.17 13.37依3.17 15.20依1.49
Reserpine    4.45依1.25c    6.78依2.30c   5.86依1.62c
L-dopa  10.45依3.26b  15.23依1.44b 14.70依1.40b
GA 225    6.15依2.98a    9.46依2.52a 5.93依2.56
GA 450    9.43依2.23b  12.56依1.80b 6.15依0.89
The values are expressed as mean 依 SEM (n=6); aP<0.05, bP<0.01 vs Reserpine group (One way ANOVA followed by Dunnett’s test). cP<0.001 
vs vehicle group (Students ‘t’ test), GA= Gentisic acid.
Table 3
Effect of gentisic acid on haloperidol induce orofacial dyskinesia in wistar rat.
Treatment 
Frequency of movement/15 min
Vacuous chewing movement Tongue protrusion
Day 7 Day 14 Day 21 Day 7 Day 14 Day 21
Vehicle 0.30依0.27  0.35依0.19  1.20依0.35 0.19依0.22 0.79依0.27 0.35依0.29
Haloperidol 2.95依0.34   2.15依0.26c  4.14依1.63 2.96依0.21  4.90依1.95c 6.13依0.45
L-dopa   1.06依0.50a   0.66依0.25b   1.30依0.41b  0.61依0.25b  1.57依0.52b  1.59依0.32b
GA 40 2.33依0.35 2.21依0.41  9.50依0.52 1.73依0.50 4.16依1.75  4.10依0.67a
GA 80 1.43依0.45   0.86依0.24b    2.43依0.60b  1.53依0.11b  2.32依1.53a  2.26依0.50b
The values are expressed as mean 依SEM (n=6); aP<0.05, bP<0.01 vs Haloperidol group (One way ANOVA followed by Dunnett’s test).  cP<0.001 
vs vehicle group (Students ‘t’ test), GA= Gentisic acid.
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is thus formed and becomes an important source of oxidative 
stress in catecholaminergic neuronal systems[19]. some 
study states that Haloperidol neurotoxicity to the inhibition 
of mitochondrial electron transfer with an enhancement 
of O2 and H2O2 production[20]. Reactive Oxygen Species 
(ROS) originating from the oxidation of Dopamine (DA) 
further participates in the pathogenesis of PD[21]. Oxidative 
stress generated as a result of mitochondrial dysfunction, 
particularly mitochondrial complex-1 impairement plays 
an important role in the PD pathogenesis[21]. Probably, there 
is not a single factor responsible for neurodegeneration; it 
appears that several factors are acting in concert. 
  Oxidative stress and consequent cell death could occur 
in the SNpc under circumstances in which there is (a) an 
increased dopamine turnover, resulting in excess peroxide 
formation; (b) a deficiency in glutathione (GSH) content, 
thereby diminishing the brains capacity to clear H2O2 or 
(c) an increase in reactive iron species, which can promote 
hydroxyl radical formation[22]. After Gentisic acid treatment, 
the significant alterations produced in Parkinson’s affected 
rodents with respect to lipid peroxidation and antioxidant 
concentration hence signifies its antioxidant potential. 
This antiperoxide action observed in Gentisic acid treated 
animals might be due to the suppression of the production 
of reactive oxygen species. This compound may be found 
to scavenge free radicals, including hydroxyl anions and 
reduce the level of lipid peroxidation in Parkinsonian 
animals. Inhibition of oxidative stress may be one of the 
possible mechanisms for the anti-Parkinson effects of 
Gentisic acid.
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